CMS’ new Cell and Gene Therapy (CGT) Access Model seeks to test whether outcomes-based agreements improve access to transformative CGTs for beneficiaries with sickle cell disease. In this article, Nimitt discusses the need for CMS to address challenges created by Medicaid out-of-state provider enrollment regulations, which present often-insurmountable barriers to care.